Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma

Exclusion criteria

• . History of prior treatment with vismodegib or any other hedgehog pathway inhibitor.
• . Radiotherapy that involved the field of the target lesion within 6 months prior to registration. Only one radiotherapy of the target lesion performed \> 6 months prior to registration is allowed. If a second radiotherapy in this field took place, patient will be excluded.
• . Any metastatic BCC
• . BCC lesion that is considered to be inoperable (e.g. medical contraindication to surgery, suspicion of bone infiltration)
• . Metatypic BCC
• . Known or suspected Gorlin-Goltz syndrome
• . Uncontrolled medical illness, including advanced malignancies (no activities of the malignancies in the past 3 years), at the discretion of the Investigator
• . History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications